Acute kidney injury induced by protein-overload nephropathy down-regulates gene expression of hepatic cerebroside sulfotransferase in mice, resulting in reduction of liver and serum sulfatides

Biochemical and Biophysical Research Communications

Volumn 390, Issue 4, 2009, Pages 1382-1388

  Zhang, Xiaowei ^a   Nakajima, Takero ^a   Kamijo, Yuji ^a,b   Li, Gang ^c   Hu, Rui ^d   Kannagi, Reiji ^e   Kyogashima, Mamoru ^e,f   Aoyama, Toshifumi ^a   Hara, Atsushi ^a  

^a SHINSHU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c HEBEI GENERAL HOSPITAL   (China)

^d HEBEI MEDICAL UNIVERSITY   (China)

^e AICHI CANCER CENTER HOSPITAL   (Japan)

^f NAGOYA CITY UNIVERSITY   (Japan)

Author keywords

Acute kidney injury; Cerebroside sulfotransferase (CST); Peroxisome proliferator activated receptor (Ppara) null mice; Protein overload nephropathy; Sphingoglycolipids; Sulfatides

Indexed keywords

CERAMIDE; CEREBROSIDE SULFATASE; GALACTOSYLCERAMIDASE; GALACTOSYLTRANSFERASE; GLYCOSPHINGOLIPID; HEPATIC CEREBROSIDE SULFOTRANSFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; SULFATIDE; SULFOTRANSFERASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; DOWN REGULATION; GENE EXPRESSION; HEMODIALYSIS; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY INJURY; LIVER; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN METABOLISM; PROTEIN OVERLOAD NEPHROPATHY;

ACUTE DISEASE; ANIMALS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; GENE EXPRESSION REGULATION; KIDNEY DISEASES; LIVER; MALE; MICE; MICE, MUTANT STRAINS; OXIDATIVE STRESS; PPAR ALPHA; PROTEINS; SULFOGLYCOSPHINGOLIPIDS; SULFOTRANSFERASES;

MAMMALIA; MURINAE; MUS; SPHINGOIDEA;

EID: 70450231609     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.10.164     Document Type: Article

References (32)

1. Ishizuka I. Chemistry and functional distribution of sulfoglycolipids. Prog. Lipid Res. 36 (1997) 245-319
2. Honke K., Zhang Y., Cheng X., et al. Biological roles of sulfoglycolipids and pathophysiology of their deficiency. Glycoconj. J. 21 (2004) 59-62
3. Nagai K., Tadano-Aritomi K., Niimura Y., et al. Higher expression of renal sulfoglycolipids in marine mammals. Glycoconj. J. 25 (2008) 723-726
4. Hara A., and Taketomi T. Occurrence of sulfatide as a major glycosphingolipid in WHHL rabbit serum lipoproteins. J. Biochem. 102 (1987) 83-92
5. Hara A., and Taketomi T. Characterization and changes of glycosphingolipids in the aorta of the Watanabe hereditable hyperlipidemic rabbit. J. Biochem. 109 (1991) 904-908
6. Kyogashima M. The role of sulfatide in thrombogenesis and haemostasis. Arch. Biochem. Biophys. 426 (2004) 157-162
7. Hara A., Uemura K., and Taketomi T. Sulfatide prolongs blood-coagulation time and bleeding time by forming a complex with fibrinogen. Glycoconj. J. 13 (1996) 187-194
8. Hara A., Kutsukake Y., Uemura K., et al. Anticoagulant activity of sulfatide and its anti-thrombotic effect in rabbit. J. Biochem. 113 (1993) 781-785
9. Hu R., Li G., Kamijo Y., et al. Serum sulfatides as a novel biomarker for cardiovascular disease in patients with end-stage renal failure. Glycoconj. J. 24 (2007) 565-571
10. Kamijo Y., Hora K., Kono K., et al. PPARα protects proximal tubular cells from acute fatty acid toxicity. J. Am. Soc. Nephrol. 18 (2007) 3089-3100
11. Lee S.S., Pineau T., Drago J., et al. Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell. Biol. 15 (1995) 3012-3022
12. Hara A., and Radin N.S. Lipid extraction of tissues with a low-toxicity solvent. Anal. Biochem. 90 (1978) 420-426
13. Li G., Hu R., Kamijo Y., et al. Establishment of a quantitative, qualitative, and high-throughput analysis of sulfatides from small amounts of sera by matrix-assisted laser desorption ionization-time of flight mass spectrometry. Anal. Biochem. 362 (2007) 1-7
14. Aoyama T., Uchida Y., Kelley R.I., et al. A novel disease with deficiency of mitochondrial very-long-chain acyl-CoA dehydrogenase. Biochem. Biophys. Res. Commun. 191 (1993) 1369-1372
15. Aoyama T., Souri M., Ushikubo S., et al. Purification of human very-long-chain acyl-coenzyme A dehydrogenase and characterization of its deficiency in seven patients. J. Clin. Invest. 95 (1995) 2465-2473
16. Aoyama T., Peters J.M., Iritani N., et al. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor α (PPARα). J. Biol. Chem. 273 (1998) 5678-5684
17. Nakajima T., Kamijo Y., Tanaka N., et al. Peroxisome proliferator-activated receptor α protects against alcohol-induced liver damage. Hepatology 40 (2004) 972-980
18. Aoyama T., Yamano S., Waxman D.J., et al. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. J. Biol. Chem. 264 (1989) 10388-10395
19. Kamijo Y., Hora K., Tanaka N., et al. Identification of functions of peroxisome proliferator-activated receptor α in proximal tubules. J. Am. Soc. Nephrol. 13 (2002) 1691-1702
20. Tanaka N., Moriya K., Kiyosawa K., et al. PPARα activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. J. Clin. Invest. 118 (2008) 683-694
21. Kamijo Y., Hora K., Nakajima T., et al. Peroxisome proliferator-activated receptor α protects against glomerulonephritis induced by long-term exposure to the plasticizer di-(2-ethylhexyl)phthalate. J. Am. Soc. Nephrol. 18 (2007) 176-188
22. Honke K., Hirahara Y., Dupree J., et al. Paranodal junction formation and spermatogenesis require sulfoglycolipids. Proc. Natl. Acad. Sci. USA 99 (2002) 4227-4232
23. Granata S., Zaza G., Simone S., et al. Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease. BMC Genomics 10 (2009) 388
24. Kendrick J., and Chonchol M.B. Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nat. Clin. Pract. Nephrol. 4 (2008) 672-681
25. Hirahara Y., Tsuda M., Wada Y., et al. cDNA cloning, genomic cloning, and tissue-specific regulation of mouse cerebroside sulfotransferase. Eur. J. Biochem. 267 (2000) 1909-1917
26. Schreck R., Albermann K., and Baeuerle P.A. Nuclear factor kappa B: an oxidative stress-responsive transcription factor of eukaryotic cells (a review). Free Radic. Res. Commun. 17 (1992) 221-237
27. Ammendola R., Mesuraca M., Russo T., et al. The DNA-binding efficiency of Sp1 is affected by redox changes. Eur. J. Biochem. 225 (1994) 483-489
28. Ramon O., Wong H.K., Joyeux M., et al. 2′-Deoxyguanosine oxidation is associated with decrease in the DNA-binding activity of the transcription factor Sp1 in liver and kidney from diabetic and insulin-resistant rats. Free Radic. Biol. Med. 30 (2001) 107-118
29. Zanetti M., Barazzoni R., and Guarnieri G. Inflammation and insulin resistance in uremia. J. Ren. Nutr. 18 (2008) 70-75
30. Gonzalez F.J., Peters J.M., and Cattley R.C. Mechanism of action of the nongenotoxic peroxisome proliferators: role of the peroxisome proliferator-activator receptor α. J. Natl. Cancer Inst. 90 (1998) 1702-1709
31. Levey A.S., Beto J.A., Coronado B.E., et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am. J. Kidney Dis. 32 (1998) 853-906
32. Sarnak M.J., Levey A.S., Schoolwerth A.C., et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108 (2003) 2154-2169